NEUROVANCE INC has a total of 22 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2006. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are LAB OS DEL DR EHSTEVE S A, MCKINNEY ANTHONY ALEXANDER and EPITECH GROUP SRL.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Canada | 2 | |
#4 | Israel | 2 | |
#5 | Republic of Korea | 2 | |
#6 | Australia | 1 | |
#7 | China | 1 | |
#8 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Piskorski Walter | 11 |
#2 | Mckinney Anthony | 10 |
#3 | Greene Matthew | 6 |
#4 | Mcmillan Brian | 6 |
#5 | Mckinney Anthony Alexander | 5 |
#6 | Chen Zhengming | 5 |
#7 | Bymaster Franklin | 5 |
#8 | Skolnick Phil | 5 |
#9 | Epstein Joseph W | 4 |
#10 | Basile Anthony | 4 |
Publication | Filing date | Title |
---|---|---|
US2018008575A1 | Methods of treating binge eating disorder | |
KR20160101012A | Novel compositions | |
US2014206740A1 | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters | |
US2014303207A1 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | |
WO2013019271A1 | Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters |